NOVO NORDISK A S (NVO)
Health Care · Pharmaceuticals · NYSE
A leading global healthcare company pioneering scientific breakthroughs to treat and defeat serious chronic diseases like diabetes and obesity.
What NOVO NORDISK A S does
Novo Nordisk is a global healthcare company specializing in the treatment of serious chronic diseases. Its core business is built upon a heritage in diabetes care, with an expanding focus on medical solutions for obesity and other chronic conditions.
Themes: diabetes care, obesity management / weight loss drugs, chronic disease treatment
Fundamentals
- Price$45.12 as of 2026-09-01 close
- Market cap$206.0B as of 2026-09-03
- 1-year return-20.1% 2025-08-29 close $56.46 → 2026-09-01 close $45.12
- P/E11.40 as of 2026-09-03
- Net margin+33.1% FY2025, SEC XBRL
- Gross margin+81.0% FY2025, SEC XBRL
- ROE+52.8% FY2025, SEC XBRL
- Debt / equity0.63 as of 2026-09-03
- Revenue growth (YoY)+5.6% as of 2026-09-03
- Revenue CAGR (3y)+20.4% SEC XBRL
- Beta1.93 as of 2026-09-03
- Last reported earningsn/a no confirmed date — as a foreign private issuer it reports on Form 6-K, which carries no earnings item code
Dividend: yield +1.0%; pays a dividend.
How NVO compares in its sector
- price-to-earnings ratiobottom 25% 197 covered Health Care peers, as of 2026-09-03
- net profit margintop 10% 426 covered Health Care peers, as of 2026-09-03
- operating margintop 10% 417 covered Health Care peers, as of 2026-09-03
- gross margintop 25% 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 507 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-09-03
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NVO is not currently in any published Top 10 list. Its scores are below.
Long-term score
59.7 #286 of 1,587 scored · #35 of 197 in Health Care
Profitability 93rd (operating margin 43.1%, return on equity 59.1%) and valuation 60th (price to earnings 11.4, price to book 7.4); weakest is long-term trend (31st, over the past 12 months this stock lagged the market by 38.2 percentage points). Scored on 5 of 6 pillars — it pays a dividend, but its filings carry no per-share series to count increases from; no annual share count in its filings.
Short-term score
38.2 #1294 of 1,683 scored · #206 of 241 in Health Care
Setup 55th: no Elliott-wave labelling currently fits its swings; momentum 54th: MACD momentum is negative; weakest is volume and participation 20th: trading volume is about normal versus its 30-day average.
Scores as of 1 Sep 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 3.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, NVO's dividend was covered by reported results (earnings payout 51%, free-cash-flow payout 88%). This describes past coverage, not a forecast.
- Earnings payout51% dividends / net income
- Free-cash-flow payout88% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How NOVO NORDISK A S looks technically
NOVO NORDISK A S (NVO) is trading 2.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 19 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day low about 21 trading days ago. It is 29.7% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 2.9% below its 200-day average, the long-term trend line — a long-term downtrend | -2.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $47.92 | $47.92 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $46.45 | $46.45 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 48.66. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 19 trading days ago — a "golden cross", a bullish long-term signal | 19 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 13.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 42.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($44.68 to $48.66) — its "stochastic" reading is 11 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 11.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $64.16 | $64.16 |
|---|---|---|
| From the 52-week high | it is 29.7% below its 52-week high (its highest price of the past year) | -29.7% |
| Above the 52-week low | it is 28.5% above its 52-week low (its lowest price of the past year) | +28.5% |
| Below the 52-week high | it is 29.7% below its highest point of the past year | 29.7% |
| Since a 20-day breakout | it made a new 20-day low about 21 trading days ago | 21 sessions |
| Since a 55-day breakout | it made a new 55-day high about 24 trading days ago | 24 sessions |
| All-time high | its highest closing price on record is $148.15 (set on 2024-06-25) | $148.15 |
| Given back of the 52-week move | over the past year its closes ranged ($35.29 to $63.98), and it has recovered roughly a third of its fall from last year’s high — 34% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $53.02 to $53.94. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 34.3% |
| From the all-time high | it is 69.5% below its all-time high | -69.5% |
| Nearest price level | it is sitting right on a support level at $44.96 — a price it turned at three times since 2025-08-06, most recently on 2026-08-17. Since 2024-09-03 it has 3 such levels below the current price and 14 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.3% |
| All-time low | its lowest closing price on record is $0.715 (set on 1996-07-30) | $0.715 |
| Above the all-time low | it is 6210.5% above its all-time low | +6,210% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 9% of the past ~6 months), which often precedes a bigger move | 9th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.32 between its high and its low — about 2.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.32 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $44.36 and $48.31 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $44.36 – $46.33 – $48.31 |
| Typical daily range (% of price) | its price moves about 2.9% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.9% |
| Stretch from the 200-day average | it is trading 1.0 daily range below its 200-day average price (2.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.0 daily range below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.74× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.8% since the prior reading | -0.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bearish engulfing | today it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-09-01 1.0% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.0% |
|---|---|---|
| Open gap | it gapped 2.6% below the previous close 3 sessions ago and has not traded back through the level it left behind at 47.19 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.6% |
| Gap filled | a 2.8% gap down opened on 2026-08-12 has been "filled" 9 sessions ago — price traded back through the level the gap left behind, and it took 5 sessions to close | 9 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 5 sessions in a row, a -7.27% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 5 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 6.1 percentage points (the stock lost 4.2% while the market gained 2.0%) | -6.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 2.0 percentage points (the stock gained 2.4% while the market gained 0.4%) | +2.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 9.4 percentage points (the stock gained 20.5% while the market gained 11.0%) | +9.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 38.2 percentage points (the stock lost 20.1% while the market gained 18.1%) | -38.2% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 2.7% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-27 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.7% of the share price. | -2.7% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 1% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $45.75 — a volume-weighted average of daily closes over 164 sessions, not a true tick-by-tick VWAP. | -1.4% |
|---|
Price levels it has turned at before
NVO last closed at $45.12 on 2026-09-01. Since 2024-09-03 it has turned at 3 prices below its last close and 14 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $44.96 | Support | 0.3% below the last close | turned there three times · 2025-08-06 to 2026-08-17 |
| $46.06 | Resistance | 2.1% above the last close | turned there twice · 2025-12-09 to 2026-05-28 |
| $43.43 | Support | 3.7% below the last close | turned there four times · 2025-11-24 to 2026-08-04 |
| $47.89 | Resistance | 6.2% above the last close | turned there four times · 2025-12-18 to 2026-07-22 |
| $41.20 | Support | 8.7% below the last close | turned there twice · 2026-04-16 to 2026-06-08 |
| $50.47 | Resistance | 11.8% above the last close | turned there five times · 2025-11-12 to 2026-07-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $48.66.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $35.01 and $40.23 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $48.66.
This reading has stood for 1 trading day, since 2026-09-01.
Read from daily closes as of 2026-09-01.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-09-01. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.57 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$47.08 range $40.14 – $63.96; median $45.09
Analyst estimates, as of 2026-08-30. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NVO
- Consensus EPS estimateDKK 5.14 next reporting period, as of 2026-08-30
- Readings revised upward33% of 3 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on core diabetes and obesity therapeutic areas","Regulatory and pricing pressures in global healthcare markets","Risks associated with international operations and supply chain management"]
Short interest (FINRA)
NVO had 33,828,864 shares of reported short interest as of the 2026-08-14 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for NVO because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 33,828,864
- Prior settlement (shares) 29,424,036
- Reported change 14.97%
- Days to cover (reported) 2.18
Reported to FINRA as of the 2026-08-14 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Eli Lilly (LLY)
- Sanofi (SNY)
- AstraZeneca (AZN)
- Merck & Co. (MRK)
- Pfizer (PFE)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NVO vs…
NOVO NORDISK A S is found in…
NVO ranks in…
Frequently asked questions
What does NOVO NORDISK A S (NVO) do?
Novo Nordisk is a global healthcare company specializing in the treatment of serious chronic diseases. Its core business is built upon a heritage in diabetes care, with an expanding focus on medical solutions for obesity and other chronic conditions.
What sector is NOVO NORDISK A S (NVO) in?
NOVO NORDISK A S (NVO) is classified in the Health Care sector. Its industry is Pharmaceuticals. It trades on NYSE.
Does NVO pay a dividend?
Yes — NOVO NORDISK A S (NVO) pays a dividend, with an indicated yield of about 1.00% (market data, as of 2026-09-03). Informational only — not financial advice.
Who are NOVO NORDISK A S's (NVO) competitors?
Notable peers of NOVO NORDISK A S (NVO) include Eli Lilly, Sanofi, AstraZeneca, Merck & Co. and Pfizer. This peer set is informational only — not financial advice.
Is NOVO NORDISK A S (NVO) overbought or oversold right now?
NOVO NORDISK A S (NVO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-09-01). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NVO come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-09-01.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.